Name: | Tobramycin |
---|---|
PubChem Compound ID: | 11340303 |
Description: | An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. |
Molecular formula: | C18H37N5O9 |
Molecular weight: | 467.515 g/mol |
Name: | Tobramycin |
---|---|
Name (isomeric): | DB00684 |
Drug Type: | small molecule |
Description: | An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. |
Synonyms: |
3'-Deoxykanamycin B; tobramycin solution for inhalation; Tobramycin Sulfate; SPRC-AB01
|
Brand: | Nebcin, Tobi, Tobramitsetin, Nebramycin Factir 6, Nebramycin Vi, Tobrasone, Tobracin, Nebramycin 6, NF 6, Sybryx, Nebramycin, Aktob, Obramycin, Nebramycin Factor 6, Tobradex, Tenemycin, Tobramaxin, Tobradistin, Distobram, Tobramycetin, Tenebrimycin, Tobrex, Gernebcin, Obracin |
Category: | Anti-Bacterial Agents, Aminoglycosides |
CAS number: | 32986-56-4 |
Indication: | For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections. |
---|---|
Pharmacology: |
Tobramycin, an aminoglycoside antibiotic obtained from cultures of Streptomyces tenebrarius, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyeliti...
show more » |
Mechanism of Action: |
Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intra...
show more » |
Absorption: | The bioavailability of tobramycin may vary because of individual differences in nebulizer performance and airway pathology. |
Half Life: | The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration. |
Toxicity: | LD50=441mg/kg (s.c. in mice) |
Affected organisms: | Enteric bacteria and other eubacteria |
Drug interaction: |
|
---|